Literature DB >> 25823547

Bladder Tumor Heterogeneity: The Impact on Clinical Treatment.

Chao Chen1, Xiang Jie Qi, Yan Wei Cao, Yong Hua Wang, Xue Cheng Yang, Shi Xiu Shao, Hai Tao Niu.   

Abstract

Bladder cancer relapse and treatment failure in most patients have often been attributed to chemoresistance in tumor cells and metastasis. Emerging evidence indicates that tumor heterogeneity may play an equally important role and extends to virtually all measurable properties of cancer cells. Although the idea of tumor heterogeneity is not new, little attention has been paid to applying it to understand and control bladder cancer progression. With the development of biotechnology, such as Gene sequencing, recent advances in understanding its generation model, original basis, consequent problems, and derived therapies provide great potential for tumor heterogeneity to be considered a new insight in the treatment of bladder cancers.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2015        PMID: 25823547     DOI: 10.1159/000370165

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  9 in total

1.  Expression and clinical significance of androgen receptor in bladder cancer: A meta-analysis.

Authors:  Jinbo Chen; Yu Cui; Peng Li; Longfei Liu; Chao Li; Xiongbing Zu
Journal:  Mol Clin Oncol       Date:  2017-08-23

2.  Targeting IL-5Rα with antibody-conjugates reveals a strategy for imaging and therapy for invasive bladder cancer.

Authors:  Michel Paquette; Luis-Guillermo Vilera-Perez; Simon Beaudoin; Nadia Ekindi-Ndongo; Pierre-Luc Boudreaut; Marc-Andre Bonin; Marie-Claude Battista; M'hamed Bentourkia; Angel F Lopez; Roger Lecomte; Eric Marsault; Brigitte Guérin; Robert Sabbagh; Jeffrey V Leyton
Journal:  Oncoimmunology       Date:  2017-05-19       Impact factor: 8.110

3.  A Systematic Review and Meta-Analysis Comparing the Safety and Efficacy of Spinal Anesthesia and Spinal Anesthesia Combined with Obturator Nerve Block in Transurethral Resection of Bladder Tumors.

Authors:  Wanxin Deng; Qiang Zhang; Hongmei Yao
Journal:  Emerg Med Int       Date:  2022-06-29       Impact factor: 1.621

Review 4.  Genetic determinants for chemo- and radiotherapy resistance in bladder cancer.

Authors:  Andrea Mari; David D'Andrea; Mohammad Abufaraj; Beat Foerster; Shoji Kimura; Shahrokh F Shariat
Journal:  Transl Androl Urol       Date:  2017-12

5.  Targeted O-glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced-stage bladder tumours.

Authors:  Sofia Cotton; Rita Azevedo; Cristiana Gaiteiro; Dylan Ferreira; Luís Lima; Andreia Peixoto; Elisabete Fernandes; Manuel Neves; Diogo Neves; Teresina Amaro; Ricardo Cruz; Ana Tavares; Maria Rangel; André M N Silva; Lúcio Lara Santos; José Alexandre Ferreira
Journal:  Mol Oncol       Date:  2017-03-02       Impact factor: 6.603

Review 6.  Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?

Authors:  Rita Azevedo; Andreia Peixoto; Cristiana Gaiteiro; Elisabete Fernandes; Manuel Neves; Luís Lima; Lúcio Lara Santos; José Alexandre Ferreira
Journal:  Oncotarget       Date:  2017-07-21

Review 7.  Tumor heterogeneity in muscle-invasive bladder cancer.

Authors:  Ho Won Kang; Wun-Jae Kim; Woonyoung Choi; Seok Joong Yun
Journal:  Transl Androl Urol       Date:  2020-12

8.  MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer.

Authors:  Hao Liu; Wang He; Bo Wang; Kewei Xu; Jinli Han; Junjiong Zheng; Jun Ren; Lin Shao; Shiping Bo; Sijia Lu; Tianxin Lin; Jian Huang
Journal:  BMC Cancer       Date:  2018-06-15       Impact factor: 4.430

9.  Inhibition of MELK produces potential anti-tumour effects in bladder cancer by inducing G1/S cell cycle arrest via the ATM/CHK2/p53 pathway.

Authors:  Song Chen; Qiang Zhou; Zicheng Guo; Yejinpeng Wang; Lu Wang; Xuefeng Liu; Mengxin Lu; Lingao Ju; Yu Xiao; Xinghuan Wang
Journal:  J Cell Mol Med       Date:  2019-12-10       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.